Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

ABSTRACT:

Importance

Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk increase is not well established in real-world populations. Even less is known about infection risk associated with rituximab, which is extensively used off-label to treat MS in Sweden.

Objective

To examine the risk of serious infections associated with disease-modifying treatments for MS.

Design, setting, and participants

This nationwide register-based cohort study was conducted in Sweden from January 1, 2011, to December 31, 2017. National registers with prospective data collection from the public health care system we

SUBMITTER: Luna G 

PROVIDER: S-EPMC6784753 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature